Department of Neurology, Medical University of Bialystok, Marii Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland.
Int J Mol Sci. 2024 Sep 29;25(19):10515. doi: 10.3390/ijms251910515.
Ischemic stroke (IS) is a critical medical condition that results in significant neurological deficits and tissue damage, affecting millions worldwide. Currently, there is a significant lack of reliable tools for assessing and predicting IS outcomes. The inflammatory response following IS may exacerbate tissue injury or provide neuroprotection. This review sought to summarize current knowledge on the IL-1 family's involvement in IS, which includes pro-inflammatory molecules, such as IL-1α, IL-1β, IL-18, and IL-36, as well as anti-inflammatory molecules, like IL-1Ra, IL-33, IL-36A, IL-37, and IL-38. The balance between these opposing inflammatory processes may serve as a biomarker for determining patient outcomes and recovery paths. Treatments targeting these cytokines or their receptors show promise, but more comprehensive research is essential to clarify their precise roles in IS development and progression.
缺血性脑卒中（IS）是一种严重的医学病症，可导致显著的神经功能缺损和组织损伤，影响着全球数百万人。目前，评估和预测 IS 结局的可靠工具严重缺乏。IS 后的炎症反应可能会加重组织损伤或提供神经保护。本综述旨在总结白细胞介素-1 家族（IL-1 家族）参与 IS 的相关知识，其包括促炎分子，如白细胞介素-1α（IL-1α）、白细胞介素-1β（IL-1β）、白细胞介素-18（IL-18）和白细胞介素-36（IL-36），以及抗炎分子，如白细胞介素-1 受体拮抗剂（IL-1Ra）、白细胞介素-33（IL-33）、白细胞介素-36A（IL-36A）、白细胞介素-37（IL-37）和白细胞介素-38（IL-38）。这些相反的炎症过程之间的平衡可能作为确定患者结局和恢复途径的生物标志物。针对这些细胞因子或其受体的治疗方法具有前景，但需要更全面的研究来阐明它们在 IS 发展和进展中的确切作用。
